Skyhawk Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
85
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$7.5M
- Investors
-
19
Skyhawk Therapeutics General Information
Description
Developer of small-molecule RNA-modulating therapies designed to treat diseases with limited treatment options. The company offers its proprietary SKYSTAR platform to discover and develop small-molecule therapies that modulate RNA, enabling the development of treatments for diseases that are difficult to address through existing therapeutic approaches.
Contact Information
Website
www.skyhawktx.comCorporate Office
- 180 3rd Avenue
- Sixth Floor
- Waltham, MA 02451
- United States
Corporate Office
- 180 3rd Avenue
- Sixth Floor
- Waltham, MA 02451
- United States
Skyhawk Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 13-May-2026 | $7.5M | Completed | Generating Revenue | ||
| 4. Later Stage VC | 06-Jul-2022 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B) | 30-Jun-2021 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 01-Jan-2019 | $100M | $108M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 23-Jan-2018 | $8M | $8M | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Skyhawk Therapeutics Comparisons
Industry
Financing
Details
Skyhawk Therapeutics Competitors (21)
One of Skyhawk Therapeutics’s 21 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Nanoviricides | Corporation | Shelton, CT | ||||
| Remix Therapeutics | Venture Capital-Backed | Watertown, MA | ||||
| Arcturus Therapeutics Holdings | Formerly VC-backed | San Diego, CA | ||||
| Spark Therapeutics | Formerly VC-backed | Philadelphia, PA |
Skyhawk Therapeutics Patents
Skyhawk Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026148020-A1 | Formulations for use in modulating rna splicing and methods of making and using the same | Pending | 31-Dec-2024 | ||
| WO-2026101897-A9 | 6-(6-(((lr,2r,3s,5s)-2-fluoro-9-azabicyclo[3.3.1jnonan-3yl) (methyl)amino)pyridazine-3-yl)-2-methylbenzo[d]oxazol-5-ol to treat huntington's disease | Pending | 05-Nov-2024 | ||
| WO-2026101897-A1 | 6-(6-{[(1r,2r,3s,5s)-2-fluoro-8-azabicyclo[3.2.1 ]octan-3-yl] (methyl)amino }pyridazin-3-yl)-2-methyl-l,3-benzoxazol-5-ol to treat huntington's disease | Pending | 05-Nov-2024 | ||
| WO-2026019893-A1 | Compositions useful for modulating splicing | Pending | 17-Jul-2024 | ||
| WO-2026019914-A1 | Compositions useful for modulating splicing | Pending | 17-Jul-2024 | C07D487/04 |
Skyhawk Therapeutics Signals
Skyhawk Therapeutics Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ABRDN Emerging Markets Equity Income | Asset Manager | Minority | ||
| Tekla World Healthcare Fund | Asset Manager | Minority | ||
| Hongsen Investment | Venture Capital | Minority | ||
| Sanofi Ventures | Corporate Venture Capital | Minority | ||
| Sphera Funds Management | Hedge Fund | Minority |
Skyhawk Therapeutics FAQs
-
When was Skyhawk Therapeutics founded?
Skyhawk Therapeutics was founded in 2015.
-
Where is Skyhawk Therapeutics headquartered?
Skyhawk Therapeutics is headquartered in Waltham, MA.
-
What is the size of Skyhawk Therapeutics?
Skyhawk Therapeutics has 85 total employees.
-
What industry is Skyhawk Therapeutics in?
Skyhawk Therapeutics’s primary industry is Drug Discovery.
-
Is Skyhawk Therapeutics a private or public company?
Skyhawk Therapeutics is a Private company.
-
What is Skyhawk Therapeutics’s current revenue?
The current revenue for Skyhawk Therapeutics is .
-
How much funding has Skyhawk Therapeutics raised over time?
Skyhawk Therapeutics has raised $304M.
-
Who are Skyhawk Therapeutics’s investors?
ABRDN Emerging Markets Equity Income, Tekla World Healthcare Fund, Hongsen Investment, Sanofi Ventures, and Sphera Funds Management are 5 of 19 investors who have invested in Skyhawk Therapeutics.
-
Who are Skyhawk Therapeutics’s competitors?
Sarepta Therapeutics, Nanoviricides, Remix Therapeutics, Arcturus Therapeutics Holdings, and Spark Therapeutics are some of the 21 competitors of Skyhawk Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process